Oncoinvent ASA: Minutes from Extraordinary General Meeting

Oncoinvent held an extraordinary general meeting on 8 January 2026 that approved an audited interim balance sheet, a reverse share split, a capital reduction and granted proxy to the board; the minutes are published on the company website. The Oslo-listed clinical-stage biotech, developer of radiopharmaceutical Radspherin, reports encouraging early clinical efficacy and no serious safety signals, with a randomized Phase 2 trial ongoing. The approved corporate actions constitute a capital-structure reset that may change share count and shareholder economics but are unlikely to be immediately market-moving absent further financial details.

Analysis

Market structure: The EGM actions (reverse share split, capital reduction, board proxy and audited interim balance sheet) signal a balance-sheet repair and float consolidation—short-term winners are large/strategic holders and potential acquirers who benefit from a cleaner cap table; retail and small liquidity providers are losers due to higher bid-ask spreads and potential dilution. For competitive dynamics, Oncoinvent remains a niche radiopharmaceutical developer; corporate housekeeping does not change therapeutic competitiveness but raises probability of near-term M&A or structured financing if Phase 2 data (US/UK/EU) stays encouraging.

Risk assessment: Tail risks include trial failure, regulatory safety findings around radium-224, inability to secure financing (leading to insolvency) or manufacturing disruptions for radium supply—each could wipe out equity (low probability, >100% downside for equity). Immediate (days) volatility should spike around financing terms; short-term (weeks–months) the key is clarity on runway and raise size; long-term (12–36 months) outcome hinges on randomized Phase 2 efficacy/safety and partner interest. Hidden dependencies include radium-224 sourcing, GMP facility scale-up constraints, and contingent liabilities from capital reduction mechanics.

Trade implications: Direct tactical long only if financing terms and post-split free-float signal runway ≥12 months—size 1–2% of portfolio with a strict 30% stop; alternatively, short/avoid due to predictable dilution risk. Relative trade: overweight liquid biotech (IBB or XBI) vs underweight/on short of Oncoinvent (OSE: ONCO) to capture idiosyncratic execution risk. Options: buy 3–6 month puts (10–25% OTM) on ONCO if available, or buy puts on XBI as a sector hedge while holding small ONCO exposure.

Contrarian angles: The market may be pricing only downside; if Oncoinvent secures a non-dilutive partnership or a financing at >NOK 50–100m with milestone-based earn-outs within 60 days, upside could be 2–5x given small post-split float and positive Phase 2 momentum. Historical parallels: small radiopharma recapitalizations that preserved trial continuity often produced outsized returns on positive readouts—but the reverse is also common. Watch for unintended consequences: reverse splits can trigger index/ownership thresholds and reduce option availability, further amplifying illiquidity.

Key Decisions for Investors

• Consider an opportunistic long of 1–2% portfolio in Oncoinvent (OSE: ONCO) only after: (a) post-split market cap < NOK 300m or clear runway ≥12 months confirmed, and (b) financing terms not >25% dilution; use a 30% stop-loss and target 200–300% upside within 12–24 months conditional on positive Phase 2 signals.
• If Oncoinvent announces an equity raise priced at a >20% discount to the pre-offer close or fails to secure >NOK 50m committed non-dilutive capital within 60 days, initiate a tactical exit or short-sized position (0.5–1% portfolio) to capture expected dilution-driven downside.
• Establish a pair trade: overweight liquid biotech ETF (IBB or XBI) by +1–2% vs benchmark and underweight/small short in Oncoinvent (0.5–1%) to isolate idiosyncratic execution risk; rebalance in 30–90 days as financing clarity emerges.
• If liquid, buy 3–6 month OTM puts on ONCO (10–25% OTM) sized to cover 50–100% of an ONCO long; if ONCO options unavailable, buy 3-month puts on XBI as a capped-cost sector hedge while holding a small ONCO exposure.
• Monitor within 30–60 days: (1) announced financing amount and pricing, (2) cash runway post-financing (target ≥12 months), (3) any partnership/M&A term sheet; treat failure to meet these as a trigger to cut exposure >75% immediately.